Benefits of a Continuous Ambulatory Peritoneal Dialysis (CAPD) Technique with One Icodextrin-Containing and Two Biocompatible Glucose-Containing Dialysates for Preservation of Residual Renal Function and Biocompatibility in Incident CAPD Patients

다국어 초록 (Multilingual Abstract)

In a prospective randomized controlled study, the efficacy and safety of a continuousambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrincontainingand two glucose-containing dialysates a day. Eighty incident CAPD patientswere randomized to two groups; GLU group continuously using four glucose-containingdialysates (n = 39) and ICO group using one icodextrin-containing and two glucosecontainingdialysates (n = 41). Variables related to residual renal function (RRF), metabolicand fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125)and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decreasein mean renal urea and creatinine clearance (-Δ1.2 ± 2.9 mL/min/1.73 m2, P = 0.027) andurine volume (-Δ363.6 ± 543.0 mL/day, P = 0.001) during 12 months, but the ICO groupdid not (-Δ0.5 ± 2.7 mL/min/1.73 m2, P = 0.266; -Δ108.6 ± 543.3 mL/day, P = 0.246).

Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICOgroup than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher inthe ICO group than the GLU group. Dialysis adequacy, β2-microglobulin clearance andblood pressure did not differ between the two groups. The CAPD technique using oneicodextrin-containing and two glucose-containing dialysates tends to better preserve RRFand is more biocompatible, with similar dialysis adequacy compared to that using fourglucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry,ISRCTN23727549]

참고문헌 (Reference)

1 Naka T, "The paradigm of IL-6: from basic science to medicine" 4 : S233-S242, 2002

2 Williams JD, "The Euro-Balance Trial : the effect of a new biocompatible peritoneal dialysis fluid(balance)on the peritoneal membrane" 66 : 408-418, 2004

3 Finkelstein F, "Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration" 16 : 546-554, 2005

4 Kendrick J, "Strategies for improving long-term survival in peritoneal dialysis patients" 5 : 1123-1131, 2010

5 Bargman JM, "Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis : a reanalysis of the CANUSA Study" 12 : 2158-2162, 2001

6 Termorshuizen F, "Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients : an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis(NECOSAD)-2" 15 : 1061-1070, 2004

7 Liao CT, "Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis" 24 : 2909-2914, 2009

8 Fan SL, "Randomized controlled study of biocompatible peritoneal dialysis solutions : effect on residual renal function" 73 : 200-206, 2008

9 Bruschi M, "Proteome profile of peritoneal effluents in children on glucose-or icodextrin-based peritoneal dialysis" 26 : 308-316, 2011

10 De Vecchi AF, "Preliminary evaluation of incremental peritoneal dialysis in 25 patients" 20 : 412-417, 2000

11 Maiorca R, "Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients : a longitudinal study" 10 : 2295-2305, 1995

12 Rocco M, "Peritoneal dialysis adequacy and risk of death" 58 : 446-457, 2000

13 Gokal R, "Metabolic and laboratory effects of icodextrin" (81) : S62-S71, 2002

14 Haag-Weber M, "Low-GDP fluid(Gambrosol trio)attenuates decline of residual renal function in PD patients : a prospective randomized study" 25 : 2288-2296, 2010

15 Davies SJ, "Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange" 23 : 2982-2988, 2008

16 Oda H, "Lipid abnormalities in end stage renal disease" 13 : 45-49, 1998

17 National Kidney Foundation, "KDOQI Clinical practice guidelines for peritoneal dialysis adequecy: guideline 2. peritoneal dialysis solute clearance targets and measurements" 49 : S103-S116, 2006

18 Wang AY, "Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients" 15 : 2186-2194, 2004

19 Viglino G, "Incremental peritoneal dialysis: effects on the choice of dialysis modality, residual renal function and adequacy" (108) : S52-S55, 2008

20 Fernström A, "Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis" 18 : 166-171, 1998

21 Takatori Y, "Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management : a randomized controlled trial" 6 : 1337-1344, 2011

22 Bouchi R, "Icodextrin increases natriuretic peptides in diabetic patients undergoing CAPD" 26 : 604-607, 2006

23 Davies SJ, "Icodextrin improves the fluid status of peritoneal dialysis patients : results of a double-blind randomized controlled trial" 14 : 2338-2344, 2003

24 Dombros N, "European best practice guidelines for peritoneal dialysis: 7 adequacy of peritoneal dialysis" 20 : ix24-ix27, 2005

25 Paniagua R, "Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial" 13 : 1307-1320, 2002

26 Woodrow G, "Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis" 15 : 862-866, 2000

27 Witowski J, "Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis" 47 : 282-293, 1995

28 Konings CJ, "Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study" 63 : 1556-1563, 2003

29 Martikainen T, "Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? a 1-year follow-up study" 39 : 410-416, 2005

30 Schwenger V, "Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products" 17 : 199-207, 2006

31 Szeto CC, "Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products : a 1-year randomized control trial" 22 : 552-559, 2007

32 Visser CE, "Cancer antigen 125 : a bulk marker for the mesothelial mass in stable peritoneal dialysis patients" 10 : 64-69, 1995

33 Bergström J, "Calculation of the protein equivalent of total nitrogen appearance from urea appearance: which formulas should be used?" 18 : 467-473, 1998

34 Kim S, "Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients : a 1-year study" 24 : 2899-2908, 2009

35 Diaz-Buxo JA, "Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance" 33 : 523-534, 1999

36 García-López E, "An update on peritoneal dialysis solutions" 8 : 224-233, 2012

37 Mistry CD, "A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD : MIDAS Study Group : Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis" 46 : 496-503, 1994

38 Wolfson M, "A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis" 40 : 1055-1065, 2002

39 Lui SL, "A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial" 60 : 966-975, 2012